While Eli Lilly and Novo Nordisk are leaders in the GLP-1 market, Becton, Dickinson and Abbott Laboratories offer better indirect exposure to the GLP-1 boom. Becton, Dickinson supplies prefillable syringes with soaring demand and is a Dividend King, while Abbott's continuous glucose monitoring devices see increased adoption alongside GLP-1 medicines.

The global bloodstream infection testing market is expected to grow at a CAGR of 4.80% through 2035, driven by rising sepsis cases, antimicrobial stewardship mandates, and adoption of rapid molecular diagnostics. North America leads the market, with the U.S. contributing 87.4% of regional revenues, while Asia Pacific shows the fastest growth. Key technologies include molecular diagnostics and whole blood testing, which are rapidly replacing traditional blood culture methods.

The global Enteric Disease Testing Market is valued at USD 4.08 billion in 2025 and is projected to reach USD 5.86 billion by 2035, growing at a CAGR of 3.70%. Growth is driven by increasing foodborne and waterborne disease prevalence, rising demand for rapid pathogen detection, and expanding adoption of multiplex molecular diagnostics. North America and Europe are leading markets, with Asia-Pacific emerging as the fastest-growing region.

The article highlights five blue-chip dividend stocks suitable for long-term buy-and-hold investing: AbbVie, McDonald's, Johnson & Johnson, Walmart, and Becton Dickinson. These companies have demonstrated decades of consecutive dividend increases and strong financial fundamentals, with dividends well-covered by earnings and solid growth prospects ahead.

The global wound irrigation systems market is projected to grow from USD 307.87 million in 2025 to USD 430.05 million by 2035, with a CAGR of 3.55%. Growth is driven by rising chronic wound prevalence, increased surgical volumes, and innovations in pulsatile lavage systems. North America leads with 40% market share, while Asia Pacific shows the fastest growth at 4.7% CAGR. Manual systems currently dominate with 53% market share, though battery-operated systems are expected to grow fastest.

The article highlights three Dividend Kings—companies with 50+ consecutive years of dividend increases—that combine strong fundamentals with reliable income growth. Johnson & Johnson (64 years of increases) benefits from its pharmaceutical and MedTech focus post-spinoff. PepsiCo (54 years) offers diversified brand portfolio and pricing power. Becton, Dickinson (53 years) provides defensive, recession-resistant revenue from medical supplies with modest growth potential.

The global microneedle drug delivery systems market is projected to grow from USD 7.04 billion in 2025 to USD 14.37 billion by 2035, with a CAGR of 7.4%. The U.S. market is expected to expand from USD 2.45 billion to USD 5.01 billion, while Europe is forecast to reach USD 4.02 billion. Growth is driven by demand for painless, self-administered drug delivery, rising biologics and vaccine adoption, and advancing transdermal technologies.

Johnson & Johnson is highlighted as a superior Dividend King investment compared to peers like Procter & Gamble, offering better dividend growth (5.7% vs 2.4% annualized) and business resilience. Despite trading at a premium valuation, J&J's diversified pharmaceutical and medical device portfolio, patent protections, and essential healthcare products make it well-positioned to weather economic uncertainty.

The global nebulizer market is projected to grow from US$1.5 billion in 2025 to US$2.2 billion by 2032 at a CAGR of 5.9%. Growth is driven by rising respiratory disease prevalence, aging populations, technological advancements in mesh and smart nebulizers, and increasing adoption of home healthcare solutions. Key market segments include jet nebulizers, ultrasonic nebulizers, and mesh nebulizers across hospitals, clinics, and home settings.

The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.

The global HPV testing and Pap test market is projected to grow from USD 3.7 billion in 2025 to USD 6.5 billion by 2034, driven by rising cervical cancer prevalence, government screening initiatives, technological advancements, and the introduction of self-sampling tests. North America leads the market with 40.5% share, while Asia-Pacific emerges as a key growth hub.

The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.